Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma industry concerns about NZ continue, after Wikileaks reveals 2004 tactics

This article was originally published in Scrip

Executive Summary

The R&D pharmaceutical industry has always had a rather shaky relationship with one of the world's toughest reimbursement bodies, namely the monopoly purchasing power held by New Zealand's pharmaceutical management agency, Pharmac. So it comes as no surprise to read – in a leaked US embassy cable on Wikileaks' website this week – of some of the tactics used by industry to improve access in this rather small market, in value terms.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts